ERBB2 and breast carcinoma: An analysis of intrinsic subtypes from the Phase 3 MONALEESA studies reported that HR+ breast cancers classified as HER2-enriched subtype were associated with improved outcomes, while the basal-like subtype had worse outcomes [23].